USP chapters, sterility and beyond-use dating

The date on a compounded vial is a different kind of date

An approved drug product carries an expiration date. Federal regulation says that date has to be determined by stability testing, and that it has to relate to the storage conditions printed on the labeling.

A compounded preparation usually carries a beyond-use date instead. FDA defines it as the date after which a compounded drug product should not be used, and describes what it is telling you: the period during which the preparation's required quality characteristics can be ensured. The agency lists those characteristics as sterility, strength, purity and freedom from particulate matter.

That is a narrower promise than an expiration date, and it is made by the compounder rather than established through an approval. The two dates look identical on a label and mean different things.

One rule does carry across. If a product is meant to be made up at the time it is dispensed, the labeling has to bear dating information for both the made-up and the unmade-up forms. Those are two separate clocks on one package.

The chapters everyone cites by number

The compounding world talks in chapter numbers, and the numbers belong to the United States Pharmacopeia. USP is a standards-setting organization, not a regulator. Its chapters become enforceable through state law and through federal rules and guidance that point at them.

Three of them do most of the work in a conversation about an injectable.

Chapter 797 covers sterile compounding, setting out minimum standards for preparing compounded sterile preparations. FDA's guidance on insanitary conditions refers readers to it for descriptions of terms like buffer room and anteroom, and treats its criteria as the reference point for a segregated compounding area.

Chapter 71 covers sterility tests. Chapter 51 covers antimicrobial effectiveness testing, which is how a preservative in a multiple-dose container is shown to actually work.

None of those chapters is an approval, and meeting them is not the same as being reviewed. They are the measuring sticks a facility is held to, and they are worth knowing by name because a marketing page will cite the number without saying what it covers.

A passing sterility test is weaker evidence than it sounds

This is the single most counterintuitive fact in the whole subject, and FDA states it plainly.

Compounding facilities producing purportedly sterile drugs under insanitary conditions should not rely on or cite a passing sterility test as an indication that the product is sterile. The agency's reasoning is that microbial contamination, when present, is not spread evenly through a batch, so a test on a sample may simply miss it.

FDA supports that with a quotation from Chapter 71 itself. The pharmacopeial procedures are not by themselves designed to ensure that a batch is sterile or has been sterilized. That is accomplished primarily by validating the sterilization process or the aseptic procedures.

The consequence for a reader is direct. Sterility is a property of a process, demonstrated by controls, and a certificate saying a sample passed is a much smaller claim than it appears to be.

Federal regulation still requires the test. For every batch of a drug product purporting to be sterile or pyrogen-free, there must be appropriate laboratory testing against those requirements, with written procedures that are followed. The test is necessary and it is not sufficient.

How a longer date gets earned

The length of a beyond-use date is not a property of the molecule. It is bought with data.

FDA's draft guidance for outsourcing facilities sets out the structure. A facility can use a default beyond-use date without stability testing, or it can run a data-driven stability program and support a longer one. The defaults are tied to how many units a facility makes over a six-month reporting period, and they stop being available above a thousand units for a sterile product.

The trade is visible: less testing means a shorter date, more testing means a longer one. A long date on a preparation is therefore a claim about the testing behind it, not a claim about the ingredient.

The same logic appears at the short end of the scale. FDA's guidance on insanitary conditions describes a narrow allowance for compounding in a segregated area. One of its three conditions is a beyond-use date that does not run past twelve hours at room temperature or twenty-four hours refrigerated. The lesser environment buys a shorter date.

What a preservative buys, in days

A multiple-dose container is entered more than once, so it needs something to stop organisms growing between entries.

FDA's guidance points at Chapter 51 for the test methods and the acceptance criteria. If those criteria are met, labeling a multiple-dose product with an in-use period of up to twenty-eight days is considered appropriate, subject to stability testing.

That number is where the familiar month-long window on multiple-dose vials comes from. It is an outcome of a specific test on a specific formulation, not a general rule about liquids in vials.

The corollary matters more. A preparation with no preservative has not been shown to resist growth after it is opened, and it does not get that window. Whether a given vial is single-dose or multiple-dose is a formulation fact with a dating consequence, and it is printed on real labels.

What an inspector is actually looking at

FDA published a list of conditions it considers insanitary at compounding facilities. Reading it is the fastest way to understand that sterility is an environment, not a step.

The list runs through air. Insufficient assurance that filters are working. No or infrequent measurement of room pressure differentials during operations. A pattern of pressure reversals from less clean areas toward cleaner ones. Missing or inadequate filtered air over the critical area.

It runs through rooms. Unsealed or loose ceiling tiles, porous or visibly dirty surfaces, ledges capable of collecting dust, and sinks or drains in the buffer room where the critical area sits. The guidance adds a footnote that sinks and drains are sources of microbial contamination.

It runs through equipment and process. Filters not graded for sterilization or used past their capacity, no post-use filter integrity testing, sterilization parameters that are not lethal to resistant organisms, and freeze-dryers not sterilized by routine cycles.

Two entries speak directly to what ends up in an injectable. Compounding with components or containers not verified to avoid contributing objectionable endotoxin. And compounding under conditions that offer insufficient assurance the finished product will meet an endotoxin specification appropriate for its route.

The conditions that trigger a recall recommendation

FDA separates out a shorter list of conditions it considers particularly serious. If any one of them exists, the agency strongly recommends that the facility immediately recall purportedly sterile drugs and stop sterile operations until it is corrected.

Vermin or other animals in or next to production. Visible microbial growth. Sources of foreign matter such as rust, glass shavings, hairs or paint chips. Aseptic manipulations performed outside a certified critical area. Exposing sterile drugs to lower-quality air for any length of time. Production while construction is underway nearby without adequate controls.

None of that is exotic. It is the ordinary failure of a room, and it is why the room is the subject of the standard rather than the powder.

What a buyer can actually ask

Ask what the date on the label is. A beyond-use date and an expiration date are different claims, and knowing which one you have been given tells you which document sits behind it.

Ask whether the preparation is single-dose or multiple-dose. That answers whether it contains a preservative, and it is the fact the in-use window depends on.

Ask what the date was based on. A default date and a date supported by a stability program are both legitimate, and they are not the same evidence.

Treat a sterility result as a required test rather than a guarantee. FDA says so in its own words, and the reasoning is about sampling, not about anyone's honesty.

Your own handling and storage instructions come from your prescriber and the labeling that arrived with the preparation. Nothing on this page is an instruction about a vial.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Insanitary Conditions at Compounding Facilities — Guidance for Industry — U.S. Food and Drug Administration, November 2020
2. Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act (draft guidance, revision 2) — U.S. Food and Drug Administration, January 2020
3. 21 CFR 211.137 — Expiration dating — Office of the Federal Register, Electronic Code of Federal Regulations, January 2026
4. 21 CFR 211.167 — Special testing requirements — Office of the Federal Register, Electronic Code of Federal Regulations, January 2026